Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;2(3):275-82.

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis

Raja Bobba  1 , Jonathan D Adachi
Affiliations
Review

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis

Raja Bobba et al. Clin Interv Aging. 2007.

Abstract

Osteoporosis in men is an increasingly recognized problem with associated fracture morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of therapy. Risedronate has demonstrated fracture efficacy in women and efficacy has been recently been investigated in men. In men, risedronate either maintains or increases bone mineral density. In placebo controlled trials it has been shown to be safe and effective in preventing fractures.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risedronate in the treatment of corticosteroid-induced osteoporosis.
Figure 2
Figure 2
Risedronate in the prevention of corticosteroid-induced osteoporosis.
Figure 3
Figure 3
Vertebral fracture incidence.
See this image and copyright information in PMC

References

    1. Boonen S, Delmas PD, Wenderoth DH, et al. Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicentre study. Osteoporos Int. 2006;17:S230–31.
    1. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–18. - PubMed
    1. Diamond TH. Pharmacotherapy of osteoporosis in men. Expert Opin Pharmacother. 2005;6:45–58. - PubMed
    1. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52. - PubMed
    1. Hawkes WG, Wehren L, Orwig D, et al. Gender differences in functioning after hip fracture. J Gerontol A Biol Sci Med Sci. 2006;61:495–99. - PubMed

MeSH terms